ChEMBL logo


ChEMBL Statistics
  Loading Statistics...

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL428690
Compound Name ALVOCIDIB
ChEMBL Synonyms NSC-649890 | Flavopiridol | HL 275 | L 86 8275 | MDL-107826A | ALVOCIDIB HYDROCHLORIDE | HMR 1275 | L-868275 | Alvocidib
Max Phase 3
Trade Names
Molecular Formula C21H20ClNO5

Additional synonyms for CHEMBL428690 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccccc4Cl
Standard InChI InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15( ...
Download InChI


  • Clinical Candidates
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names

Alternate Forms of Compound in ChEMBL


Molecule Features

CHEMBL428690 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Unclassified Parenteral:Unclassified Topical:Unclassified Black Box:Unclassified Availability Type:Unclassified

Mechanism of Action

Mechanism of Action ChEMBL Target References
Cyclin-dependent kinase 1 inhibitor Cyclin-dependent kinase 1 PubMed PubMed
Cyclin-dependent kinase 2 inhibitor Cyclin-dependent kinase 2 PubMed PubMed
Cyclin-dependent kinase 4 inhibitor Cyclin-dependent kinase 4 PubMed PubMed
Cyclin-dependent kinase 6 inhibitor Cyclin-dependent kinase 6 PubMed PubMed
Cyclin-dependent kinase 7 inhibitor Cyclin-dependent kinase 7 PubMed PubMed
Cyclin-dependent kinase 9 inhibitor Cyclin-dependent kinase 9 PubMed PubMed


MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Breast Neoplasms, MaleD018567EFO:0006861male breast carcinoma1ClinicalTrials
Esophageal NeoplasmsD004938EFO:0002916esophageal carcinoma2ClinicalTrials
Leukemia, LymphoidD007945EFO:0004289lymphoid leukemia2ClinicalTrials
Lymphoma, Large B-Cell, DiffuseD016403EFO:0000403diffuse large B-cell lymphoma1ClinicalTrials
Breast NeoplasmsD001943EFO:0000305breast carcinoma1ClinicalTrials
Hematologic NeoplasmsD019337EFO:0001642lymphoid neoplasm1ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-CellD015451EFO:0000095chronic lymphocytic leukemia2ClinicalTrials
Endometrial NeoplasmsD016889EFO:0004230endometrial neoplasm2ClinicalTrials
Lymphoma, B-Cell, Marginal ZoneD018442EFO:0000191MALT lymphoma1ClinicalTrials
Lymphoma, Mantle-CellD020522EFO:1001469Mantle cell lymphoma1ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
MelanomaD008545EFO:0000389cutaneous melanoma2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0002890renal carcinoma2ClinicalTrials
Waldenstrom MacroglobulinemiaD008258EFO:0002616macroglobulinemia1ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials

Clinical Data ALVOCIDIB
The Cochrane Collaboration ALVOCIDIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL428690. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


ChEMBL_ID Target Name Organism Score
CHEMBL4878 Cytochrome P450 1B1 Homo sapiens 0.992
CHEMBL4159 Endoplasmic reticulum-associated amyloid beta-peptide-binding protein Homo sapiens 0.937
CHEMBL2231 Cytochrome P450 1A1 Homo sapiens 0.868
CHEMBL5332 Mitogen-activated protein kinase 7 Homo sapiens 0.764
CHEMBL242 Estrogen receptor beta Homo sapiens 0.294


ChEMBL_ID Target Name Organism Score
CHEMBL1075280 Dual specificity protein kinase CLK1 Mus musculus 1.000
CHEMBL5776 Mitogen-activated protein kinase kinase kinase 7 Homo sapiens 0.997
CHEMBL2231 Cytochrome P450 1A1 Homo sapiens 0.958
CHEMBL4878 Cytochrome P450 1B1 Homo sapiens 0.954
CHEMBL5332 Mitogen-activated protein kinase 7 Homo sapiens 0.838
CHEMBL4045 AMP-activated protein kinase, alpha-1 subunit Homo sapiens 0.790
CHEMBL3384 Protein kinase N1 Homo sapiens 0.672
CHEMBL5072 Ephrin type-B receptor 1 Homo sapiens 0.586
CHEMBL5619 DNA-(apurinic or apyrimidinic site) lyase Homo sapiens 0.324
CHEMBL5698 NUAK family SNF1-like kinase 2 Homo sapiens 0.296
CHEMBL4954 Ephrin type-A receptor 3 Homo sapiens 0.252
CHEMBL242 Estrogen receptor beta Homo sapiens 0.220
CHEMBL4924 Ribosomal protein S6 kinase alpha 6 Homo sapiens 0.211
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.204

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
401.9 401.103 3.3 2 94.14 ZWITTERION

HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 3 0 6 3 0

ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
6.16 9.28 3.27 .74 3 28 0.61

Structural Alerts

There are 3 structural alerts for CHEMBL428690. To view alerts please click here.

Compound Cross References

Wikipedia Alvocidib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL428690

ACToR 131740-09-5
Atlas flavopiridol
BindingDB 5655
ChEBI 47344
DrugBank DB03496
eMolecules 32176532
Guide to Pharmacology 5680
IBM Patent System 973DC714CF5E88265EAFBADCD41A456E
MolPort MolPort-006-169-102
Nikkaji J564.052K
PharmGKB PA452627
PubChem 5287969
PubChem: Thomson Pharma 14757147
ZINC ZINC000021288966

UniChem REST Service Call: spacer